Literature DB >> 11126384

Genes and viruses in hepatobiliary neoplasia.

M E Reeves1, R P DeMatteo.   

Abstract

Hepatobiliary neoplasms comprise a significant portion of the worldwide cancer burden. Advances in basic science research have led to rapid progress in our understanding of the molecular events responsible for these dreaded diseases. The genetic changes associated with hepatocellular carcinoma (HCC) have received the most attention. Aflatoxin B1 exposure leads to mutations in the p53 tumor suppressor gene, most commonly a transversion in codon 249 that leads to a substitution of serine for arginine in the p53 protein. Numerous other tumor suppressor genes, oncogenes, and tumor gene pathways are altered in HCC. Hepatitis B virus (HBV) infection is strongly associated with HCC. HBV may cause HCC either directly via the HBV X protein, or indirectly by causing liver inflammation and cirrhosis. Hepatitis C virus (HCV) infection is also associated with HCC. Recent evidence suggests that the HCV core protein may play a role in hepatocarcinogenesis. Several inherited metabolic diseases are associated with HCC. It is likely that these diseases cause HCC indirectly by causing cirrhosis. The molecular pathogenesis of cholangiocarcinoma and gallbladder cancer has not been well defined. However, multiple tumor suppressor genes and oncogenes, including p53 and K-ras, are altered in these tumors. Further molecular characterization of hepatobiliary tumors may lead to earlier diagnosis, better staging, improved treatment planning, and the development of more effective therapies.

Entities:  

Mesh:

Year:  2000        PMID: 11126384     DOI: 10.1002/1098-2388(200009)19:2<84::aid-ssu2>3.0.co;2-0

Source DB:  PubMed          Journal:  Semin Surg Oncol        ISSN: 1098-2388


  12 in total

1.  Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document.

Authors:  S A Khan; B R Davidson; R Goldin; S P Pereira; W M C Rosenberg; S D Taylor-Robinson; A V Thillainayagam; H C Thomas; M R Thursz; H Wasan
Journal:  Gut       Date:  2002-11       Impact factor: 23.059

2.  Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers.

Authors:  Tanios Bekaii-Saab; Mitch A Phelps; Xiaobai Li; Motoyasu Saji; Laura Goff; John Sae Wook Kauh; Bert H O'Neil; Stephanie Balsom; Catherine Balint; Ryan Liersemann; Vasily V Vasko; Mark Bloomston; William Marsh; L Austin Doyle; Gilian Ellison; Michael Grever; Matthew D Ringel; Miguel A Villalona-Calero
Journal:  J Clin Oncol       Date:  2011-04-25       Impact factor: 44.544

3.  Clinical implication of recurrent copy number alterations in hepatocellular carcinoma and putative oncogenes in recurrent gains on 1q.

Authors:  Tae-Min Kim; Seon-Hee Yim; Seung-Hun Shin; Hai-Dong Xu; Yu-Chae Jung; Cheol-Keun Park; Jong-Young Choi; Won-Sang Park; Mi-Seon Kwon; Heike Fiegler; Nigel P Carter; Mun-Gan Rhyu; Yeun-Jun Chung
Journal:  Int J Cancer       Date:  2008-12-15       Impact factor: 7.396

4.  The value of serum CA 19-9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis.

Authors:  Cynthia Levy; James Lymp; Paul Angulo; Gregory J Gores; Nicholas Larusso; Keith D Lindor
Journal:  Dig Dis Sci       Date:  2005-09       Impact factor: 3.199

5.  Beta2-GPI: a novel factor in the development of hepatocellular carcinoma.

Authors:  Xue Jing; Yun-Feng Piao; Ye Liu; Pu-Jun Gao
Journal:  J Cancer Res Clin Oncol       Date:  2010-03-04       Impact factor: 4.553

6.  Comparison of hepatocellular carcinoma in American and Asian patients by tissue array analysis.

Authors:  Tae-Jin Song; Yuman Fong; Sung-Jin Cho; Mithat Gönen; Michael Hezel; Scott Tuorto; Sang-Yong Choi; Young-Chul Kim; Sung-Ock Suh; Bum-Hwan Koo; Yang-Seok Chae; William R Jarnagin; David S Klimstra
Journal:  J Surg Oncol       Date:  2012-01-10       Impact factor: 3.454

7.  The alteration of PTEN tumor suppressor expression and its association with the histopathological features of human primary hepatocellular carcinoma.

Authors:  X-W Wan; M Jiang; H-F Cao; Y-Q He; S-Q Liu; X-H Qiu; M-C Wu; H-Y Wang
Journal:  J Cancer Res Clin Oncol       Date:  2003-03-07       Impact factor: 4.553

8.  Chromogenic in situ hybridization analysis of Epidermal Growth Factor Receptor gene/chromosome 7 numerical aberrations in hepatocellular carcinoma based on tissue microarrays.

Authors:  Evangelos Tsiambas; Loukas Manaios; Costas Papanikolopoulos; Dimitrios N Rigopoulos; Dimitrios Tsounis; Andreas Karameris; Aspasia Soultati; Antigoni Koliopoulou; Christos Kravvaritis; Theodoros Sergentanis; Efstratios Patsouris; Spyridon Dourakis
Journal:  Pathol Oncol Res       Date:  2009-09       Impact factor: 3.201

9.  Mutational analysis of BRAF in gallbladder carcinomas in association with K-ras and p53 mutations and microsatellite instability.

Authors:  Angelica A Saetta; Pollyanthi Papanastasiou; Nikolaos V Michalopoulos; Fanie Gigelou; Penelope Korkolopoulou; Thaleia Bei; Efstratios Patsouris
Journal:  Virchows Arch       Date:  2004-06-19       Impact factor: 4.064

Review 10.  Cholangiocarcinoma: a site-specific update on the current state of surgical management and multi-modality therapy.

Authors:  Michael K Turgeon; Shishir K Maithel
Journal:  Chin Clin Oncol       Date:  2019-09-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.